Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Exclusion Criteria

• •History of HCT less than 2 years prior to enrollment;
• •Immune suppression therapy less than 1 year prior to enrollment;
• •Active graft versus host disease;
• •Current diagnosis or history of lymphoma or other malignancy;
• •Current active infection;
• •History of serious opportunistic infection (e.g., bacterial \[Legionella and Listeria\]; tuberculosis \[TB\]; invasive fungal infections; or viral, parasitic, and other opportunistic infections);
• •Positive TB skin test, positive Quantiferon-TB Gold TB test, positive chest X-ray, or a recent exposure to TB
• •Congestive heart failure defined by an ejection fracture \<50% measured by ECHO;
• •Demyelinating disorders (e.g., central nervous system \[CNS\] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome);
• •Hematologic abnormalities (e.g., pancytopenia, aplastic anemia);
• •Hepatitis B infection (active or chronic carrier);
• •Latex sensitivity;
• •Pregnancy or breastfeeding;
• •Known or suspected allergy to adalimumab or related products;
• •Participation in simultaneous therapeutic study that involves an investigational study drug or agent within 4 weeks of study enrollment;
• •Requirement for live vaccine exposure that would be expected to occur during the time frame of the study; or
• •Any other social or medical condition that the Investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.